Invention Grant
- Patent Title: 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors
-
Application No.: US16669598Application Date: 2019-10-31
-
Publication No.: US11377438B2Publication Date: 2022-07-05
- Inventor: Ashok Arasappan , Ian M. Bell , Michael J. Breslin , Christopher James Bungard , Christopher S. Burgey , Harry R. Chobanian , Jason M. Cox , Anthony T. Ginnetti , Deodial Guy Guiadeen , Kristen L. G. Jones , Mark E. Layton , Hong Liu , Jian Liu , James J. Perkins , Shawn J. Stachel , Linda M. Suen-Lai , Zhe Wu
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Baerbel R. Brown; Catherine D. Fitch
- Main IPC: C07D401/12
- IPC: C07D401/12 ; C07D401/14 ; C07D409/14 ; C07D413/14 ; C07D417/14 ; C07D471/04 ; C07D491/04 ; C07D471/08 ; C07D487/04 ; C07D491/048 ; C07D495/04
Abstract:
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
Information query
